As we have gained a greater understanding of cancer biology, therapeutic interventions have evolved from a one-size-fits-all approach to more targeted approaches, which afford patients not only longer lives but increased quality of life. Cell therapies, including chimeric antigen receptor (CAR) T-cell therapy, are emerging as promising treatments, especially for hematological malignancies. However, many challenges remain in the development of this emerging class of therapeutics, from deepening responses in blood-based tumors to expanding efficacy in solid tumors.
Download this whitepaper to learn more about:
- The mechanisms behind response
- Resistance and toxicity to cell therapies
- Identifying key biomarkers